Results by group264

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 264

Outcome	Group	Category	Value	Units
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 10 mg	Any AE	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 110 mg	Any AE	6	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 200 mg	Any AE	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 250 mg	Any AE	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 125 mg	Any AE	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 200 mg	Any AE	4	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 250 mg	Any AE	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 300 mg	Any AE	4	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 10 mg	Any AE at least possibly related to navitoclax	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 110 mg	Any AE at least possibly related to navitoclax	4	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 200 mg	Any AE at least possibly related to navitoclax	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 250 mg	Any AE at least possibly related to navitoclax	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 125 mg	Any AE at least possibly related to navitoclax	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 200 mg	Any AE at least possibly related to navitoclax	4	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 250 mg	Any AE at least possibly related to navitoclax	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 21/21 Day Cycle: 300 mg	Any AE at least possibly related to navitoclax	4	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 10 mg	Any AE with NCI CTCAE Grade ≥ 3	2	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 110 mg	Any AE with NCI CTCAE Grade ≥ 3	4	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 200 mg	Any AE with NCI CTCAE Grade ≥ 3	3	Participants
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)	Navitoclax 14/21 Day Cycle: 250 mg	Any AE with NCI CTCAE Grade ≥ 3	2	Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00481091/results

API reference For AI assistants

Results by group264

Sources 3

Read this list from software.